[go: up one dir, main page]

Qureshi, 2007 - Google Patents

Hepatitis C virus—biology, host evasion strategies, and promising new therapies on the horizon

Qureshi, 2007

Document ID
9878587905050151
Author
Qureshi S
Publication year
Publication venue
Medicinal Research Reviews

External Links

Snippet

Hepatitis C reduces the quality of life for some 170 million people around the globe and is one of the most prevalent diseases on the planet. It is caused by the hepatitis C virus (HCV) that is replicated by an error‐prone polymerase and therefore undergoes rapid evolution. To …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
    • C12N2770/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Qureshi Hepatitis C virus—biology, host evasion strategies, and promising new therapies on the horizon
Li et al. Innate immune responses in hepatitis C virus infection
Tan et al. Hepatitis C therapeutics: current status and emerging strategies
Sharma Hepatitis C virus: molecular biology & current therapeutic options
Thimme et al. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection
Scheel et al. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
Hügle et al. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C
Pawlotsky et al. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27–March 1, 2003
Dymock Emerging therapies for hepatitis C virus infection
Kumthip et al. The role of HCV proteins on treatment outcomes
Belousova et al. Recent advances and future directions in the management of hepatitis C infections
Meshram et al. Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections
Bhopale et al. Emerging drugs for chronic hepatitis C
Wang et al. Recent advances in prevention and treatment of hepatitis C virus infections
Guan et al. The knowledge on HCV: from the discovery to the elimination
Mozer-Lisewska et al. The incidence and significance of pattern-recognition receptors in chronic viral hepatitis types B and C in man
AU2012347785B2 (en) Methods and compositions for treating viral diseases
Li Innate immune recognition of hepatitis C virus
Davis et al. Hepatitis C virus infection—pathobiology and implications for new therapeutic options
Eksioglu Hepatitis C virus’ initial encounters: mechanisms of innate immunity
TWI402065B (en) The application for inhibiting hcv replication by hypericin in ava-5 cells
Hassan et al. Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies
Tsukiyama-Kohara et al. Host-Targeting Antivirals for Treatment of Hepatitis C
Brown Exploring the Molecular Landscape of Hepatitis C Virus: Insights into Viral Replication and Host Interactions
Garde Mouse Models for the Study of Viral Hepatitis:(intra) cellular innate immunity